SCHEMBL3889458

SCHEMBL3889458

CC=C=NC(=O)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 4/20 0.39
CES1 P23141 4/20 0.39
ALDH1A1 P00352 3/20 0.39
TSHR P16473 3/20 0.39
DAO P14920 1/20 0.39
NAPRT Q6XQN6 1/20 0.39
TDP1 Q9NUW8 4/20 0.39
MAPT P10636 3/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 1/20 0.39
GAA P10253 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 3/20 0.39
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
CA9 Q16790 2/20 0.39
MAPK1 P28482 1/20 0.39
HDAC3 O15379 1/20 0.39
IDO1 P14902 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5200457 0.82 ALDH1A1 (0.45) CES2CES1ALDH1A1TDP1MAPT
SCHEMBL3901954 0.81 CES2 (0.43) CES2CES1ALDH1A1TDP1MAPT
SCHEMBL3888131 0.81 CES2 (0.43) CES2CES1ALDH1A1TSHRMAPT
SCHEMBL3898425 0.80 HDAC8 (0.50) ALDH1A1TDP1MAPTKMT2AKDM4E
SCHEMBL3889487 0.80 PARP1 (0.49) ALDH1A1TSHRTDP1MAPTKMT2A
SCHEMBL3889889 0.79 CES2 (0.50) CES2CES1ALDH1A1KMT2AKDM4E
SCHEMBL6276155 0.79 CES2 (0.50) CES2CES1ALDH1A1TSHRTDP1
SCHEMBL6280933 0.78 HDAC1 (0.50) ALDH1A1MAPTKMT2AGAARAB9A
SCHEMBL3890043 0.78 CES2 (0.50) CES2CES1MAPTKMT2ARAB9A
SCHEMBL3900741 0.78 PLK1 (0.44) ALDH1A1TSHRMAPTKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495018-B2 Substituted 1,3-thiazole compounds, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-02-24 US disclosed
US-7199124-B2 JNK inhibitor TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-04-03 US disclosed
US-20050080113-A1 Medicinal compositions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-14 US disclosed
US-20040063946-A1 Jnk inhibitor TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-01 US disclosed
EP-1402900-A1 MEDICINAL COMPOSITIONS Takeda Chemical Industries, Ltd. (JP) 2004-03-31 EP disclosed
US-20040053973-A1 Substituted 1,3-thiazole compounds, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-18 US disclosed
EP-1364949-A1 JNK INHIBITOR Takeda Chemical Industries, Ltd. (JP) 2003-11-26 EP disclosed
EP-1268474-A2 SUBSTITUTED 1,3-THIAZOLE COMPOUNDS, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 2003-01-02 EP disclosed
WO-2001074811-A2 SUBSTITUTED 1,3-THIAZOLE COMPOUNDS, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080113-A1 Medicinal compositions TNF, TRAF6, MMP8 CES2 4154/4885CES1 2916/4885ALDH1A1 3345/4885
US-20040053973-A1 Substituted 1,3-thiazole compounds, their production and use MAPK1, MAP4K2, MAPK4 CES2 4112/4885CES1 3741/4885ALDH1A1 1660/4885
US-20040063946-A1 Jnk inhibitor MAPK1, MAPK7, MAP3K7 CES2 3461/4885CES1 3130/4885ALDH1A1 2596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.